Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.
IT sector may remain range-bound amid global uncertainty: Amnish Aggarwal
Amnish Aggarwal of Prabhudas Lilladher suggests a positive outlook for the Indian market due to tax cuts, increased capital expenditure, and favorable monsoon forecasts. While
April 17, 2025